NC H1029

Establishes a "Right to Try" program allowing eligible patients with life-threatening or severely debilitating illnesses to access individualized investigational drugs, biological products, and devices that are customized based on the patient's genetic profile, including gene therapy and neoantigen vaccines.

Defines eligible patients as those who have exhausted FDA-approved treatment options, received physician recommendation, and provided written informed consent (or parental/guardian consent for minors) after full disclosure of risks, potential outcomes, and that insurance may not cover the treatment.

Prohibits manufacturers from being required to provide the treatments and allows them to charge patients or provide treatments free; specifies that heirs are not liable for outstanding debts if the patient dies during treatment.

Protects healthcare providers from disciplinary action or loss of licensing/Medicare certification solely for recommending these treatments and prohibits state officials from blocking eligible patients' access, with exceptions for standard medical advice and Medicaid coverage denials.

Appropriates $50,000 nonrecurring funding to the Department of Health and Human Services for the 2024-2025 fiscal year to implement the program, effective October 1, 2024.